Recent News
October 18,
2018
Zosano Pharma to Host Key Opinion Leader Meeting on New Treatments for Migraine and the Migraine Patients’ Perspective
October 16,
2018
Zosano Appoints New Chief Financial Officer
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray, or ADAM technology. Our lead clinical asset, M207, has completed the pivotal ZOTRIP trial. Zosano is focused on developing products where rapid administration of established molecules with known safety and efficacy profiles provides an increased benefit to patients, for markets where patients remain underserved by existing therapies.
Fast Acting
Therapeutic blood levels obtained more rapidly than with oral administration.
SIMPLE
Ready. Set. Apply. Three easy steps for administration.
Safe
We use known therapeutics with well-established safety and efficacy profiles.